NCT02018627 is a Phase 2/Phase 3 clinical trial of Xeris glucagon in Type 1 Diabetes, sponsored by Steven J. Russell, MD, PhD.

Who is sponsoring NCT02018627?

NCT02018627 is sponsored by Steven J. Russell, MD, PhD.

What drugs are being tested in NCT02018627?

Interventions in NCT02018627: Xeris glucagon, Lilly glucagon.

What condition does NCT02018627 study?

NCT02018627 studies Type 1 Diabetes.

Is NCT02018627 still recruiting?

NCT02018627 is currently completed. Last updated 17 September 2019.

Are results published for NCT02018627?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2019-09-17 · How we verify

NCT02018627

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

Completed Phase 2/Phase 3 Results posted Last updated 17 September 2019

What this trial tests

Phase 2/Phase 3 trial testing Xeris glucagon in Type 1 Diabetes in 20 participants. Completed in 2 August 2018.

Timeline

1 April 2014

Primary endpoint
2 August 2018

2 August 2018

Quick facts

Lead sponsor	Steven J. Russell, MD, PhD
Phase	Phase 2/Phase 3
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	crossover
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 April 2014
Primary completion	2 August 2018
Estimated completion	2 August 2018
Sites	1 location across United States

Drugs / interventions tested

Xeris glucagon — full drug profile →
Lilly glucagon — full drug profile →

Conditions studied

Type 1 Diabetes — all drugs for Type 1 Diabetes →

Sponsor

Steven J. Russell, MD, PhD — full company profile →

Who can join

Adults 21 to 80, any sex, with Type 1 Diabetes. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

Tmax
Time frame: every 2 minutes for 1 hour post-dose of each glucagon
tmax for Xeris vs. Lilly (non-inferiority)

Sponsor's own description

This study will test the hypothesis that micro-doses of Xerisol Glucagon (Xeris Pharmaceuticals) will be non-inferior by pharmacokinetic and pharmacodynamic criteria vs. micro-doses of Glucagon for Injection (Eli Lilly).

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Type 1 Diabetes

Currently open trials in the same condition.

NCT07061574 — A Randomized Phase 1/2 Trial of Low Dose Anti-thymocyte Globulin (ATG) With Subsequent Adalimumab or Verapamil in New On · Phase 1, PHASE2 · recruiting
NCT07360080 — Long-Term Outcomes of Teplizumab in Routine Clinical Care · recruiting
NCT07457580 — Real-World Study of Patients With Type 1 Diabetes Treated With Teplizumab as Part of Managed Access Programs (MAPs) · recruiting
NCT07212179 — Safety and Feasibility of a Self-Learning Bolus Calculator With Simplified Meal Announcement in Adolescents With Type 1 · NA · recruiting
NCT07287943 — To Study the Efficacy and Safety of Medtronic 780G Insulin Pump in People With Gastroparesis and Type 1 Diabetes. · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02018627 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Steven J. Russell, MD, PhD
Last refreshed: 17 September 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02018627.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing